Sessions are scheduled in local time (CEST)
Munich Hall
Mini Oral session
Date
Thu, 16.05.2024
Room
Munich Hall
Time
08:30 - 10:00
Chairs
- Peter A. Fasching (Erlangen, Germany)
- Thomas Bachelot (Lyon, France)
- Cristina Saura Manich (Barcelona, Spain)
Mini Oral session 1 (ID 50)
182MO - Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HER2+ Metastatic Breast Cancer (mBC) Previously Treated With Trastuzumab Emtansine (T-DM1): Updated Overall Survival (OS) Results of the Randomized, Phase 3 DESTINY-Breast (DB-)02 Study (ID 493)
Lecture Time
08:30 - 08:35
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Sung-Bae Kim (Seoul, Korea, Republic of)
Mini Oral session 1 (ID 50)
267MO - Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) Retreatment (RTx) After Recovery From Grade (Gr) 1 Interstitial Lung Disease/Pneumonitis (ILD) (ID 500)
Lecture Time
08:35 - 08:40
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Hope S. Rugo (San Francisco, CA, United States of America)
Mini Oral session 1 (ID 50)
One LBA TBC (ID 1146)
Lecture Time
08:40 - 08:45
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Mini Oral session 1 (ID 50)
Invited Discussant 182MO, 267MO and one LBA TBC (ID 1147)
Lecture Time
08:45 - 09:03
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Peter A. Fasching (Erlangen, Germany)
Mini Oral session 1 (ID 50)
183MO - Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial (ID 484)
Lecture Time
09:03 - 09:08
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Hope S. Rugo (San Francisco, CA, United States of America)
Mini Oral session 1 (ID 50)
1MO - HER2DX assay and survival outcomes: an individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer (ID 839)
Lecture Time
09:08 - 09:13
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Guillermo Villacampa Javierre (Barcelona, Spain)
Mini Oral session 1 (ID 50)
2MO - Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2– metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial (ID 483)
Lecture Time
09:13 - 09:18
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Mafalda Oliveira (Barcelona, Spain)
Mini Oral session 1 (ID 50)
Invited Discussant 183MO, 1MO and 2MO (ID 1148)
Lecture Time
09:18 - 09:36
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Thomas Bachelot (Lyon, France)
Mini Oral session 1 (ID 50)
3MO - Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE (ID 495)
Lecture Time
09:36 - 09:41
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Christine Desmedt (Leuven, Belgium)
Mini Oral session 1 (ID 50)
4MO - Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: a translational analysis (ID 684)
Lecture Time
09:41 - 09:46
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Paul H. Cottu (Paris, CEDEX 5, France)
Mini Oral session 1 (ID 50)
Invited Discussant 3MO and 4MO (ID 1149)
Lecture Time
09:46 - 09:59
Session Name
Room
Munich Hall
Date
Thu, 16.05.2024
Time
08:30 - 10:00
Speakers
- Cristina Saura Manich (Barcelona, Spain)